Avocet AvoSure PT
This article was originally published in The Gray Sheet
System for consumer prothrombin time self-testing gains FDA clearance, announced Dec. 16. The hand-held meter, which will be launched in mid-January at a list price of approximately $750, reads a disposable reagent strip that requires a drop of blood. Avocet received its first FDA clearance in 1998 to market AvoSure PT Pro+ for physician point-of-care use
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.